You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK

Showing 1 - 25 of 1,010
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK Phosphorylation Trial in Harbin (crizotinib for rearrangement-negative, high phosphorylated ALK patients)

Completed
  • ALK Phosphorylation
  • crizotinib for rearrangement-negative, high phosphorylated ALK patients
  • Harbin, Heilongjiang, China
    Harbin Medical University Cancer Hospital
Mar 19, 2023

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

ALK Positive NSCLC Trial in Guangzhou (Loratinib)

Recruiting
  • ALK Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Oct 19, 2023

Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

Recruiting
  • Non-small-cell Lung Carcinoma
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023

Iruplinalkib in Treatment of ALK-Positive Non-Small Cell Lung

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Aug 8, 2023

ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

Not yet recruiting
  • ALK Gene Mutation
  • +2 more
  • Pembrolizumab Combined With Bevacizumab and Chemotherapy
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Jul 14, 2022

Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)

Not yet recruiting
  • Radiotherapy Side Effect
  • +2 more
  • SBRT/SRS/radiation therapy
  • Stockholm, Sweden
    Karolinska University Hospital
Feb 16, 2023

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

ALK-positive NSCLC Trial in Shanghai (Alkotinib Capsules)

Recruiting
  • ALK-positive Non-small Cell Lung Cancer
  • Alkotinib Capsules
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Nov 28, 2022

NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

Recruiting
  • Non-small Cell Lung Cancer Stage IIIB
  • ALK Gene Mutation
  • Alectinib Oral Product
  • Mexico City, Mexico
    Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
Jan 26, 2023

ALK-positive NSCLC Trial in Jilin (XZP-3621)

Not yet recruiting
  • ALK-positive NSCLC
  • Jilin, Chang Chun, China
    Jilin Province Cancer Hospital
Jul 29, 2022

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

Plasma NGS for Assessment, Characterization, Evaluation of ALK

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Plasma Next Generation Sequencing (NGS)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 26, 2023

ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 31, 2023

NSCLC Trial in Shanghai (WX-0593)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Jiao Tong University Chest Hospital
Mar 24, 2023

Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

Not yet recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • (no location specified)
Jul 7, 2023

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Paris, France
  • +1 more
Sep 27, 2022

Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • Orange, California
  • +13 more
Nov 7, 2022

NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

Terminated
  • Non-small Cell Lung Cancer
  • Davis, California
  • +1 more
Dec 22, 2022

NSCLC Trial in United States (brigatinib)

Terminated
Has Results
  • Non-Small Cell Lung Cancer
  • Denver, Colorado
  • +3 more
Jan 10, 2023

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

Advanced NSCLC Trial in India (Lorlatinib)

Completed
  • Advanced Non-Small Cell Lung Cancer
  • New Delhi, Delhi, India
  • +11 more
Sep 13, 2022

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)

Not yet recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Providence, Rhode Island
    Rhode Island Hospital, Brown University
Mar 2, 2023

NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)

Available
  • Non-Small Cell Lung Cancer
  • ALK Gene Rearrangement Positive
  • Stanford, California
  • +3 more
Oct 18, 2022